MedPacto, Inc.

As of June 30, 2026, MedPacto, Inc. carries a market capitalization of 107.80B, placing it among publicly traded companies globally. Its enterprise value stands at 73.79B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, MedPacto, Inc. has 34.28M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 21.59, and the price-to-book ratio stands at 2.73.

These figures are as of June 30, 2026. The EV/Sales ratio of 14.77 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 73.79B versus a market cap of 107.80B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, MedPacto, Inc. maintains a current ratio of 23.06, meaning it holds 23.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.76, indicating elevated leverage, while an interest coverage ratio of -113.21 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, MedPacto, Inc. posted a negative return on equity (ROE) of -30.76, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -28.93, reflecting losses generated across the asset base. The company generates approximately 91.23M in revenue per employee across its workforce of 54.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 13.29 indicates how many times MedPacto, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, MedPacto, Inc.'s stock has declined approximately 23.34% over the past 52 weeks. The 50-day moving average sits at 2,856.20, while the 200-day moving average is 4,274.63.

Over the twelve months ended June 30, 2026, MedPacto, Inc. generated 4.99B in revenue and converted that into -14.14B in net income, yielding earnings per share of -412.32. EBITDA reached -14.38B, while operating income came in at -15.42B.

As of June 30, 2026, MedPacto, Inc. holds 35.49B in cash and equivalents against 1.48B in total debt, resulting in a net debt position of -6.53B. Total book value stands at 39.50B, with working capital of 37.30B providing operational flexibility.

MedPacto, Inc. produced -12.18B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -241.02M in capital expenditures, free cash flow totaled -12.42B - equivalent to -362.23 per share.

Over the twelve months ended June 30, 2026, MedPacto, Inc. posted a gross margin of 8.34, reflecting its pricing power and cost economics. The operating margin of -308.64 and net profit margin of -283.09 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -11.52: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.60, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to MedPacto, Inc. shareholders.

MedPacto, Inc.'s most recent stock split took place on October 4, 2023 with a 257:301 split ratio.

As of June 30, 2026, MedPacto, Inc. has an Altman Z-Score of 15.94, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.